The protective role of coenzyme Q10 in renal injury associated with extracorporeal shockwave lithotripsy: a randomised, placebo-controlled clinical trial

Authors

  • Julia Carrasco,

    Corresponding author
    1. Department of Urology, Reina Sofia University Hospital, Cordoba, Spain
    • Correspondence: Julia Carrasco, Department of Urology, Reina Sofia University Hospital, Avda. Menendez Pidal s/n, CP: 14004, Cordoba, Spain.

      e-mail: juliacv83@hotmail.com

    Search for more papers by this author
  • Francisco J. Anglada,

    1. Department of Urology, Reina Sofia University Hospital, Cordoba, Spain
    Search for more papers by this author
  • Juan P. Campos,

    1. Department of Urology, Reina Sofia University Hospital, Cordoba, Spain
    Search for more papers by this author
  • Jordi Muntané,

    1. Department of General Surgery, Virgen del Rocio University Hospital/IBiS/CSIC/University of Seville, Seville, Spain
    2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD o Ciberehd), Instituto de Salud Carlos III, Madrid, Spain
    Search for more papers by this author
  • Maria J. Requena,

    1. Department of Urology, Reina Sofia University Hospital, Cordoba, Spain
    Search for more papers by this author
  • Javier Padillo

    1. Department of General Surgery, Virgen del Rocio University Hospital/IBiS/CSIC/University of Seville, Seville, Spain
    2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD o Ciberehd), Instituto de Salud Carlos III, Madrid, Spain
    Search for more papers by this author

  • These results are protected by a patent at the Spanish Office of Patents and Trademarks (Reference: P201131992)

Abstract

Objective

  • To determine the efficacy of coenzyme Q10 (CoQ10) in preventing renal injury in patients with lithiasis undergoing extracorporeal shockwave lithotripsy (ESWL).

Patients and Methods

  • Prospective, randomised, double-blind, placebo-controlled clinical trial of 100 patients with renal lithiasis who were treated with ESWL.
  • The patients were distributed randomly into two groups receiving either placebo or CoQ10 (200 mg/day), a powerful antioxidant with vasoactive properties, orally administered during the week before ESWL and for 1 week after.
  • Renal dysfunction markers, vasoactive hormones, oxidative stress, plasma levels of several interleukins and vascular resistance index (VRI) using Doppler ultrasound were evaluated the week before ESWL, 2 h before ESWL and at 2 h, 24 h and 7 days after ESWL.

Results

  • There was a significant increase in glomerular filtration (P = 0.013), as well as a decrease in the albumin/creatinine ratio and the β2-microglobulin level (P = 0.02) after 1 week of treatment in the CoQ10 group. These changes were maintained at the follow-up after ESWL.
  • The administration of CoQ10 was associated with improvement in vasoactive hormone parameters, VRI and interleukin levels. These improvements were maintained until the end of the follow-up period.
  • However, the administration of CoQ10 was not associated with significant changes in the oxidative stress parameters.

Conclusion

  • Our results indicate that CoQ10 administration improves renal function and vasoactive and inflammation parameter values, allowing for preconditioning before the tissue insult caused by ESWL.

Ancillary